地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172431432
传真:15172469628
邮箱:sales@amyjet.com

美国Neuro Probe公司专业提供用于趋化实验的耗材(Transwell),更好地服务于药筛和基础实验研究领域。着重开发研究细胞活性实验相关的耗材,从第一代用于趋化实验的Boyden Chamer(单孔小室)到48微孔板的趋化小室,再到今天的ChemTx System他们始终与科学实验的步伐保持一致,追求创新,不断地开发新产品以满足多样化的实验需求。
Neuro Probe was founded in the late 1960’s with an initial focus on the development and manufacture of chronic stereotactic equipment. In the early 1970’s, corporate growth and diversification lead to the development and production of chemotactic instruments, beginning with the modified Boyden chamber and then assorted blind well chambers. In 1980, the 48-well microchemotaxis chamber was developed, in collaboration with Dr. Edward Leonard and Dr. Werner Falk working at the National Institutes of Health. This chamber has become a standard in the field and has served as a basis for the development of many new products. Most recently introduced is the ChemoTx® system. Please visit the Products section of our website for more information on specific products.
Neuroprobe的主要产品包括:
ChemoTx®
Chemotaxis Chambers
Single Well Chambers
Filters
Replacement Gaskets
Chemotaxis Accessories
Protein Crystallography
Cell Settling Chambers
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
<艾美捷科技代理Hypermol品牌全系列产品
Hypermol是一家德国生物科技公司,专注于肌动蛋白(actin)及肌动蛋白结合蛋白领域的技术开发与产品供应。其核心定位是成为“肌动蛋白纯化与修饰专家”,服务于全球生命科学研究、药物研发及生物技术产业。

▍Hypermol产品线
● 肌动蛋白工具箱:Actin-Toolkits利用肌动蛋白作为工具,用于分析和研究具有肌动蛋白结合位点的配体(ligands)的功能与结构。Actin-Toolkits 适用于特定用于分析和表征配体-肌动蛋白相互作用的方法。
● 肌动蛋白试用装试剂盒:Actin-Trialkits适用于:测试肌动蛋白结合配体的生物学活性;表征未知蛋白质或其结构域与G型或F型肌动蛋白的特异性相互作用;需要少量肌动蛋白的实验方案。
● 细胞骨架蛋白:Hypermol提供多种肌动蛋白标记物,涵盖骨骼肌肌动蛋白、心肌肌动蛋白、平滑肌肌动蛋白和非肌肉肌动蛋白。所有这些肌动蛋白均可进行荧光或其他生化修饰。
● 缓冲液:Hypermol缓冲液采用分析纯化学试剂和超纯水配制而成。
● 染色试剂盒与添加剂:即用型设计,操作迅捷,使用具有超高光稳定性的ATTO荧光标记鬼笔环肽,可快速染色单根肌动蛋白丝。该产品完美适用于免疫荧光样本的双重或多重染色;此处还提供即用型短保质期稳定组分作为添加剂。
● 分析试剂:可靠的高品质必需品。
● 抗体:Hypermol提供创新型ATTO染料的高性能二抗以及一系列经过验证的针对细胞骨架蛋白的一抗。Hypermol的ATTO染料标记二抗提供多种荧光颜色,具有卓越的光稳定性,支持长时间成像。
▍Hypermol部分产品列表
| 品名 | 货号 | Protein |
| Actin-Toolkit F-Actin Binding (alpha skeletal muscle actin) - 4x1.0 mg | 8010-01 | Actin (α-Actin) |
| Actin-Toolkit G-Actin Binding (alpha skeletal muscle actin) | 8020-01 | Actin (α-Actin) |
| Actin-Toolkit Fluorescence Microscopy ATTO390 - skeletal muscle actin | 8082-01 | Actin (α-Actin) |
| Actin-Toolkit Fluorescence Microscopy ATTO390-Actin - cardiac actin | 8820-01 | Actin (α-Actin) |
| Actin-Tookit Fluorometry - Pyrene Actin | 8030-01 | Actin (α-Actin) |
| Actin-Toolkit Crystallography | 8050-01 | Actin (α-Actin) |
| Actin-Toolkit Microinjection (Rhodamine-Actin, skeletal muscle actin) | 8060-01 | Rhodamine-Actin |
| Actin-Toolkit Electron Microscopy (rabbit skeletal muscle alpha-actin) | 8070-01 | Rhodamine-Actin |
| Actin-Toolkit TIRFM (ATTO488-Actin) | 8093-01 | Rhodamine-Actin |
| Actin-Toolkit ELISA (alpha skeletal muscle actin) | 8121-01 | Biotin-Actin (biotinylated α-skeletal muscle actin) |
| Actin-Toolkit Microinjection (ATTO565-Actin, skeletal muscle actin) | 8061-01 | Biotin-Actin (biotinylated α-skeletal muscle actin) |
| Actin-Toolkit SPR (alpha skeletal muscle actin) | 8090-01 | Biotin-Actin (biotinylated α-skeletal muscle actin) |
| Actin-Toolkit G-Actin Binding (alpha cardiac actin) | 8200-01 | Biotin-Actin (biotinylated α-skeletal muscle actin) |
| Actin-Toolkit F-Actin Binding (alpha cardiac actin) | 8100-01 | Biotin-Actin (biotinylated α-skeletal muscle actin) |
| Actin-Toolkit Fluorescence Microscopy ATTO488-Actin - skeletal muscle actin | 8083-01 | ATTO488-Actin (α-Actin) |
| Actin-Toolkit Microinjection ( Rhodamine alpha-cardiac actin, bovine) | 8600-01 | ATTO488-Actin (α-Actin) |
| Actin-Toolkit Electron Microscopy (bovine alpha-cardiac actin) | 8700-01 | ATTO488-Actin (α-Actin) |
| Actin-Toolkit ELISA (alpha cardiac actin) | 8122-01 | ATTO488-Actin (α-Actin) |
| Actin-Toolkit SPR (alpha cardiac muscle actin) | 8900-01 | ATTO488-Actin (α-Actin) |
| Actin-Toolkit F-Actin Binding (alpha skeletal muscle actin) - 6x250 µg | 8010-02 | ATTO488-Actin (α-Actin) |
| Actin-Tookit Fluorometry - Actin488 | 8033-01 | Actin 488 (α- skeletal muscle actin) |
| Actin-Toolkit Fluorescence Microscopy ATTO488-Actin - cardiac actin | 8830-01 | ATTO488-Actin (α-cardiac actin) |
| Actin-Toolkit Fluorescence Microscopy (ATTO532-Actin, skeletal muscle actin) | 8085-01 | ATTO488-Actin (α-cardiac actin) |
| Actin-Toolkit Fluorescence Microscopy (ATTO532-Actin, alpha-cardiac actin) | 8850-01 | ATTO488-Actin (α-cardiac actin) |
| Actin-Toolkit TIRFM (ATTO647-Actin) | 8097-01 | ATTO647-Actin (α-Actin) |
| Actin-Tookit Fluorometry - Actin550 | 8034-01 | ATTO647-Actin (α-Actin) |
| Actin-Tookit Fluorometry - Actin647 | 8035-01 | Actin 647 (α- skeletal muscle actin) |
| Actin-Toolkit Fluorescence Microscopy ATTO594 Actin - skeletal muscle actin | 8087-01 | ATTO594-Actin (α-Actin) |
| Actin-Toolkit Fluorescence Microscopy ATTO647 Actin - skeletal muscle actin | 8088-01 | ATTO647-Actin (α-Actin) |
<艾美捷科技代理AxisPharm品牌全系列产品
AxisPharm是一家专业的分析服务提供商,致力于为科学研究界和工业界提供高质量的分析服务。凭借先进的仪器设备和专业的技术团队,AxisPharm在生物分析、化学分析和质量控制领域树立了良好的声誉。AxisPharm公司的产品线包括:PEG 连接子、用于药物递送的脂质、荧光染料、单击化学试剂、聚聚乙二醇,共聚物、可裂解的连接子、抗体和抗体药物偶联物ADC、ADC 有效载荷、细胞生物学试剂、脱氧核糖核酸、修饰语、探针、合成肽、目标特定链接器、硫醇反应性接头、酸反应性连接子、胺反应性连接子、羰基反应性连接子、探针、修饰符。

▍AxisPharm产品线
● PEG连接子:聚合物聚乙二醇是多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 用于药物递送的脂质:在药物递送系统中起着至关重要的作用,特别是在脂质体、脂质纳米颗粒或脂质胶束等脂质制剂中。脂质提供结构稳定性,增强药物溶解度,实现控释,并促进靶向药物递送。
● 荧光染料:也称为荧光团或荧光探针,是吸收一种波长的光并以更高波长发射的化合物,从而产生可见荧光。它们是生物学研究中的重要工具,用于标记和检测蛋白质、核酸和细胞等生物分子,从而在显微镜、流式细胞术和实时荧光定量 PCR 等应用中实现灵敏和精确的可视化。
● 点击化学试剂:具有高特异性和最少的副产物,简化了复杂的合成过程。因此,它们在分子生物学、材料科学和药物化学中发挥着至关重要的作用。
● 聚合物聚乙二醇:多分散聚乙二醇 (PEG) 聚合物,是一种从石油中提取的聚醚化合物,具有从工业制造到医药的许多应用。
● 可裂解连接子:一类重要的分子,广泛应用于药物发现、化学生物学和材料科学等各个领域。这些连接子充当两个或多个分子实体之间的连接桥,可以在特定条件下选择性地裂解,从而释放附着的分子。这一特性使它们成为生物活性化合物靶向药物递送、成像和控释的有吸引力的工具。
● 抗体及抗体-药物偶联物及细胞生物学试剂:种类丰富可选择。
● ADC有效载荷:作为 ADC 的三个主要成分之一,有效载荷是高活性和有毒的药物分子,通过化学连接子附着在抗体上。有效载荷可以是小分子、蛋白质毒素、生物活性肽、酶,甚至放射性核素。通过适当的接头与适当的载体系统耦合的有效载荷可能会显示出靶向药物递送的特异性和有效性的提高。
● 脱氧核糖核酸:DNA 是脱氧核糖核酸的缩写,是一种包含所有生物体发育和功能的遗传指令的分子。DNA 由四个基本组成部分组成,称为核苷酸,由糖、磷酸基团和含氮碱基组成。
● 改性剂:改变其他分子或材料特性的化合物。在药物研发领域,改性剂在新型药物递送系统和生物医学设备的设计和优化中发挥着至关重要的作用。一种常见的改性剂类型是官能团,它是赋予分子特定化学和物理性质的原子的特定排列。
● 探针:AxisPharm 提供各种靶标特异性探针,例如叶酸 PEG、生物素 PEG、PROTAC PEG、荧光染料探针和图像探针。探针是一类含有官能团的化合物,旨在选择性地与生物分子(如酶、受体和核酸)相互作用。这些官能团包括荧光染料、生物素和亲和标签等,可以检测和定量复杂生物系统中的特定分子。
| Different Types of Polyethylene Glycol PEG Linkers in Stock | ||||
| Acid PEG | Diketone PEG | Non-PEG linker | PFP ester PEG | Sugar PEG β-Glucuronide Linker |
| Aldehyde PEG | DNP PEG | PEG-t-butyl ester | Phosphonate PEG | Sulfonic acid PEG |
| Alkyne PEG | DBCO PEG | PEG-X-PEG | Polymer PEG | TCO PEG |
| Amino PEG | DSPE PEG | Peptide Linkers | Propargyl PEG | Tetrazine PEG |
| Aminooxy PEG | Fluorescent PEG | Lipid PEG | PROTAC Linker | Homobifunctional PEG |
| Azide PEG | Fmoc PEG | M-PEG | Silane PEG | Bromo PEG |
| BCN-PEG | Folate PEG | Maleimide PEG | SPDP PEG | Tosylate PEG |
| Benzyl-PEG | Thiol PEG | MeNH-PEG | Branched PEG | Bis-Sulfone PEG |
| Biotin PEG | Hydrazide PEG | NHS ester PEG | HyNic PEG | DOTA Reagent DOTA PEG |
| Bis-PEG-acid | Hydroxy PEG | Boc-PEG | Bis-PEG-NHS | Iodo PEG |
| Bis-PEG-NHS | Cleavable Linkers | |||
| Lipids for Drug Delivery | ||||
| Biotinyl Cap PE | Dodecanyl PE | Other Lipid | Phosphatidylcholine | Phosphatidylethanolamine |
| Biotinyl PE | Glutaryl PE | PDP PE | Phosphoglycerol | Ptd Thioethanol |
| Caproylamine PE | Ionizable Lipid | PE MCC | Phosphoserine | Succinyl PE |
| Cationic Lipid | Lipid PEG | Cyanur PE | MPB PE | |
| Fluorescent Dye | ||||
| AF Dyes | Cyanine Dyes | MB Dyes | Rhodamine Dye | Rox (carboxy-X-rhodamine) Dye |
| APDye Fluors | DNP PEG | JOE | R6G | Peptide Labeling Reagents |
| Bodipy Probes | Fluorescein (FAM) | Pyrene Probes | TAMRA Dye | Classic Fluorescent Dyes |
| IR Fluors | Quenchers | Coumarin 343 | ||
| Click Chemistry Tools & Reagents | ||||
| Alkyne PEG | BCN-PEG | PTAD Linker | Tetrazine PEG | Click Chemistry Auxiliary Reagents |
| Azide PEG | DBCO PEG | TCO PEG | Methylcyclopropene Linkers | |
| Polymer PEG | ||||
| Acrylate | Biotin | Fmoc | Lipoamide | Silane |
| Active ester | Boc | Folate | Maleimide | Stearic acid |
| Aldehyde | Carboxylic acid | guanlian1010 | MW 2000 | TCO |
| Amine | Cholesterol | Hydrazide | MW 5000 | Thiol |
| Azide | DBCO | Hydroxyl | Polysarcosine | |
| Cleavable Linkers | ||||
| -S-S-Cleavable | PC Cleavable | Disulfide Linkers | Dde Cleavable Linkers | β-Glucuronide Linkers |
| Cleavable Peptide | diazo biotin probes | DTSSP crosslinker | Photocleavable Biotin | |
| Antibody and Antibody Drug Conjugate (ADC) | ||||
| Inotuzumab | Trastuzumab | Enfortumab | Labetuzumab govitecan | Mirvetuximab soravtansine (solution) |
| Vobramitamab | Disitamab | Mirzotamab | Loncastuximab tesirine | Trastuzumab deruxtecan (solution) |
| Polatuzumab | Ozuriftamab | Brentuximab | Trastuzumab deruxtecan | ADC Control Human IgG1-Deruxtecan (DAR 8) |
| Gemtuzumab | Inebilizumab | Datopotamab | Cofetuzumab pelidotin | Glembatumumab vedotin |
| Daratumumab (PBS) | Denintuzumab | Sacituzumab govitecan | Belantamab mafodotin | Trastuzumab duocarmazine |
| Praluzatamab | Naratuximab | Tisotumab | Enfortumab vedotin-ejfv | Trastuzumab emtansine (solution) |
| Lorvotuzumab | Rolinsatamab | Trastuzumab emtansine | Telisotuzumab vedotin | Enfortumab vedotin-ejfv (solution) |
| Izeltabart | Mipasetamab | Datopotamab deruxtecan | Gemtuzumab ozogamicin | Brentuximab vedotin (solution) |
| Lupartumab | Iladatuzumab | ORM-5029 | Cantuzumab ravtansine | Depatuxizumab mafodotin |
| Cantuzumab | Briobacept | Ifinatamab deruxtecan | Tusamitamab ravtansine | ADC Control Human IgG1-Deruxtecan (DAR 4) |
| Lonigutamab | Tamrintamab | Tisotumab vedotin | Zilovertamab vedotin | Depatuxizumab MMAE |
| Moxetumomab | Sacituzumab | Disitamab vedotin | Polatuzumab vedotin | ADC Control Human IgG1-vcMMAF |
| Azintuxizumab | Upifitamab | Belantamab | Pivekimab | Sacituzumab govitecan (solution) |
| Lifastuzumab | Glembatumumab | Patritumab deruxtecan | Farletuzumab ecteribulin | |
| Payloads and Linker modified Payloads | ||||
| Exatecan | Belotecan HCl | SGD-1882 | Dolastatin 10 | MC-Val-Cit-PAB-Doxorubicin |
| SN 38 | Gimatecan | MMAF | Calicheamicin | Gly3-Val-Cit-PAB-MMAE |
| Amrubicin | Taltobulin | Auristatin E | Eribulin Mesylate | SuO-Glu-Val-Cit-PAB-MMAE |
| Mitomycin C | Dxd | Chlorambucil | Soblidotin (Auristatin PE) | Fmoc-G-amino-CH2O acetyl-Exetecan |
| Deruxtecan analog | Lurtotecan | PF-06380101 | Deruxtecan analog 2 | DM1-MCC-PEG3-Biotin |
| sulfo-SPDB-DM4 | Exatecan mesylate | Auristatin F | Paclitaxel | GGFG-amino-CH2O-acetyl Exetecan |
| Rubitecan | MC-DM1 | MMAF-methyl ester | MC-MMD10 | Mal-PEG8-Val-Cit-PAB-MMAE |
| (4-NH2)-Exatecan | Irinotecan | Doxorubicin-SMCC | SPDB-DM4 | DBCO-PEG4-Val-Cit-PAB MMAF |
| Topotecan | PNU-159682 | MMAD | 10-Hydroxycamptothecin | Topotecan Hydrochloride |
| CL2A-SN38 | DM4 | 7-Ethylcamptothecin | ||
| Cell Biology Reagents | ||||
| Neuro-DiO, lipophilic tracer | VU (5-Vinyl-uridine) | CM-DiI, lipophilic tracer | LumiTracker ER Green | ER-Tracker Red (BODIPY TR Glibenclamide) |
| Annexin V-AF 647 conjugate | DAPI, blue fluorescent nucleic acid stain | Propidium Iodide | Deep-Red Fluorescent Nissl Stain | MitoCLox, mitochondrial lipid peroxidation probe |
| Annexin V-AF 488 conjugate | LumiTracker Mito Rhodamine 123 | LumiTracker Mito Green FM | RAPID DiI, lipophilic tracer | Laurdan (6-Dodecanoyl-2-dimethylaminonaphthalene) |
| Annexin V, His Tag | Thiazole Orange | SynaptoProbe® Red | LumiTracker ER Red | Linear Polyacrylamide for Nucleic Acid Precipitation |
| DiD, lipophilic tracer | RH 237, potentiometric probe | SynaptoProbe® Green | RAPID DiO, lipophilic tracer | Fluo-4 AM, green fluorescent calcium indicator |
| DiR, lipophilic tracer | Hoechst 33342, blue fluorescent nucleic acid stain | LumiTracker® Mito Red FM | DiI, lipophilic tracer | YODi-1, green fluorescent nucleic acid stain |
| DNA | ||||
| CPG solid supports | DNA Stains | Modified Triphosphates | phosphoramidite | |
| Probes | ||||
| Biotin PEG | Folate PEG | Image Probes | PROTAC Linker | |
| Amine reactive Linkers | ||||
| Acid PEG | Aldehyde PEG | Bromo PEG | Maleimide PEG | NHS ester PEG |
▍AxisPharm提供的服务
● 蛋白质组学服务:提供质谱分析、蛋白质鉴定和定量服务。专注于生物标志物分析,帮助客户在复杂的生物样本中发现和验证潜在的生物标志物。
● 代谢组学服务:利用先进的LC-MS/MS技术进行代谢物分析,提供通路洞察,帮助客户理解代谢途径和生物过程。
● 高级LC-MS/MS服务:用于PK分析和HPLC分离,确保高精度和高效率的研究结果,提供PK/PD研究,支持药物开发和临床前研究。
▍AxisPharm部分产品列表
| Cat# | Name | M.W. | Purity |
| AP15197 | Exatecan | 435.45 | ≥98% |
| AP15072 | SN 38 | 392.4 | ≥95% |
| AP15226 | Amrubicin | 483.47 | ≥98% |
| AP15664 | Mitomycin C | 334.3 | ≥98% |
| AP15203 | 10-Hydroxycamptothecin | 364.35 | ≥95% |
| AP15204 | 7-Ethylcamptothecin | 376.41 | ≥95% |
| AP15210 | Rubitecan | 393.35 | ≥95% |
| AP15211 | (4-NH2)-Exatecan | 403.43 | ≥95% |
| AP15206 | Topotecan | 421.5 | ≥95% |
| AP15207 | Topotecan Hydrochloride | 425.5 | ≥95% |
| AP15202 | Belotecan HCl | 433.5 | ≥95% |
| AP15208 | Gimatecan | 447.5 | ≥95% |
| AP15227 | Taltobulin | 473.65 | ≥99% |
| AP15201 | Dxd | 493.48 | ≥95% |
| AP15209 | Lurtotecan | 518.56 | ≥95% |
| AP15196 | Exatecan mesylate | 531.55 | ≥98% |
| AP15200 | Deruxtecan analog 2 | 579.58 | ≥95% |
| AP15205 | Irinotecan | 586.68 | ≥95% |
| AP15224 | PNU-159682 | 641.62 | ≥98.24% |
| AP15220 | Soblidotin (Auristatin PE) | 701.98 | ≥95% |
| AP15225 | SGD-1882 | 725.8 | ≥98% |
| AP15213 | MMAF | 732 | ≥95% |
| AP15216 | Auristatin E | 732 | ≥95% |
| AP15311 | Chlorambucil | 304.21 | ≥98 |
| AP15219 | PF-06380101 | 743.01 | ≥95% |
| AP15214 | Auristatin F | 746 | ≥95% |
| AP15215 | MMAF-methyl ester | 745.99 | ≥98% |
| AP15187 | Doxorubicin-SMCC | 762.8 | ≥98% |
| AP15217 | MMAD | 771.06 | ≥98% |
<艾美捷科技代理GenoSensor Corporation品牌全系列产品
GenoSensor Corporation是一家基因组技术公司,专注于为从事基因组研究和/或需要基因组解决方案的生命科学领域客户提供产品和服务。公司产品线包括:微RNA芯片、PCR/实时定量PCR(QPCR)试剂盒、基因组改变分析工具,DNA提取试剂盒以及临床应用的专用试剂盒及试剂。

▎GenoSensor Corporation产品线
● MicroRNA Expression Profiling
MicroRNA是约21个核苷酸(NT)的非编码小RNA,参与转录后调控,并在多种细胞和生物体中表达。GenoExplorer™ microRNA生物芯片和检测方法为研究microRNA表达及其谱分析提供了支持。microRNA芯片包括人、小鼠、大鼠、果蝇、秀丽隐杆线虫、拟南芥以及其他物种的芯片,GenoExplorer™微阵列以高重复性、高信噪比和高灵敏度为标志,展现出高品质性能。
| 货号 | 品名 | 产品描述 | 规格 |
| 1101C | GenoExplorer™ microRNA kit - human 4 | GenoExplorer™ microRNA chips, labeling reagent, hybridization buffer and washing solutions | 4 reactions |
| 1102C | GenoExplorer™ microRNA kit - human 20 | 20 reactions | |
| 1111C | GenoExplorer™ microRNA kit - mouse/rat 4 | 4 reactions | |
| 1112C | GenoExplorer™ microRNA kit - mouse/rat 20 | 20 reactions | |
| 1121C | GenoExplorer™ microRNA kit - C. elegans 4 | 4 reactions | |
| 1122C | GenoExplorer™ microRNA kit - C. elegans 20 | 20 reactions | |
| 1131C | GenoExplorer™ microRNA kit - Drosophila melanogaster 4 | 4 reactions | |
| 1132C | GenoExplorer™ microRNA kit - Drosophila melanogaster 20 | 20 reactions | |
| 1141C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 4 | 4 reactions | |
| 1142C | GenoExplorer™ microRNA kit - Arabidopsis thaliana 20 | 20 reactions | |
| 1199 | GenoExplorer™ microRNA for other species | - | |
| 1301 | GenoExplorer™ microRNA array labeling kit | GenoExplorer™microRNA labeling kit | 20 reactions |
| 1302 | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | GenoExplorer™microRNA labeling kit is ONLY available with purchase of full kits | 4 reactions |
| 1201C | GenoExplorer™ microRNA cihp - human 4 | GenoExplorer™ microRNA chips and 2x hybridization buffer | 4 chips (4 arrays) |
| 1202C | GenoExplorer™ microRNA cihp - human 20 | 20 chips (20 arrays) | |
| 1211C | GenoExplorer™ microRNA cihp - mouse/rat 4 | 4 chips (4 arrays) | |
| 1212C | GenoExplorer™ microRNA chip - mouse/rat 20 | 20 chips (20 arrays) | |
| 1221C | GenoExplorer™ microRNA chip - C. elegans 4 | 4 chips (4 arrays) | |
| 1222C | GenoExplorer™ microRNA chip - C. elegans 20 | 20 chips (20 arrays) | |
| 1231C | GenoExplorer™ microRNA chip - Drosophila melanogaster 4 | 4 chips (4 arrays) | |
| 1232C | GenoExplorer™ microRNA chip - Drosophila melanogaster 20 | 20 chips (20 arrays) | |
| 1241C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 4 | 4 chips (4 arrays) | |
| 1242C | GenoExplorer™ microRNA chip - Arabidopsis thaliana 20 | 20 chips (20 arrays) | |
| 1299 | GenoExplorer™ microRNA for other species | - | |
| 1401C | GenoExplorer™ microRNA probe set - human | 1 complete GenoExplorer™ microRNA probe set for human in 384-well plates | 500 pmol |
| 1411C | GenoExplorer™ microRNA probe set - mouse/rat | 1 complete GenoExplorer™ microRNA probe set for mouse in 384-well plates | 500 pmol |
| 1421C | GenoExplorer™ microRNA probe set - C. elegans | 1 complete GenoExplorer™ microRNA probe set for C. elegans in a 384-well plate | 500 pmol |
| 1431C | GenoExplorer™ microRNA probe set - Drosophila melanogaster | 1 complete GenoExplorer™ microRNA probe set for Drosophila melanogaster in a 384-well plate | 500 pmol |
| 1441C | GenoExplorer™ microRNA probe set - Arabidopsis thaliana | 1 complete GenoExplorer™ microRNA probe set for Arabidopsis thaliana in a 384-well plate | 500 pmol |
| 1499 | GenoExplorer™ microRNA for other species | 1 complete GenoExplorer™ microRNA probe set in 384-well plates | - |
| 1501 | 2x Hybridization buffer | 2x hybridization buffer with optimized salt and formamide | 5 x 1ml |
| 1502 | 2x printing buffer | 2x phosphate printing buffer pH 8.3 | 100 ml |
| 1503 | Blocking buffer | Blocking buffer (or Buffer S for GenoExplorer array kit) | 5 x 1ml |
| 1504 | Washing buffers | Washing buffer I and II (concentrated) | 120 and 50 ml |
● MicroRNA qRT-PCR Analysis
GenoExplorer™microRNA qRT-PCR试剂盒提供了一个简单且高灵敏度的工具,用于定量检测特定的miRNA。该试剂盒可测量miRNA的成熟形式或前体形式,或者同时测量两种形式。
<| 货号 | 品名 | 产品描述 | 规格 |
| 2001 | GenoExplorer™ miRNA qRT-PCR Kit-100 | Provides complete set for miRNA quantitation including first-strand cDNA synthesis and SYBR® Green I qPCR reagent mix. (primers not included, see Cat# 2003 and 2004) | 100 reactions |
| 2002-10 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-10 | Provides necessary core components to generate miRNA first-strand cDNA for miRNA expression quantitation. | 10 reactions |
| 2002-50 | GenoExplorer™ miRNA First-Strand cDNA Core Kit-50 | 50 reactions | |
| 2003 | GenoExplorer™ miRNA qPCR Primer Sets | Provides specific primer pair for miRNA quantitation analysis (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and reference primer sets (Cat# 2004). Refer miRBase for available genes and primers. | 100 µl |
| 2004 | GenoExplorer™ miRNA qPCR Reference Primer Sets | Reference primer as an internal control reference (3µM each). Suggest to combine with GenoExplorer™ miRNA qRT-PCR Kit-100 (Cat# 2001) and GenoExplorer™ miRNA qPCR Primer Sets (Cat# 2003).Selection of human-U6, human-U44, human-5SrRNA; mouse-U6, mouse-5SrRNA; rat-U6, rat-5SrRNA; Drosophila-U6 and 5SrRNA | 100 µl |
| 2005 | GenoExplorer™ 2X qPCR Mix | 2X SYBR® Green I qPCR mix, specifically for miRNA and small RNA amplification and quantification, containing all PCR reagents and polymerase | 750 µl |
● Gene Expression Profiling
GenoExplorer™ 基因表达谱分析生物芯片包括:针对选定基因及其可变剪接异构体的定制微阵列,涵盖人、小鼠、大鼠及其他物种的完整基因文库,以及用于表达研究的基因子集。
| 品名 | 产品描述 |
| GenoExplorer™ Human Genome Chips | Microarray contains 29K human microRNA sequences |
| GenoExplorer™ Human Functional Genomics Chips | Microarrays include the subsets of functional genes and ESTs, such as signal transduction, liver enzymes, etc. |
| Custom Chips | We will help you design your custom chips for the genes that you are interested in. |
● COVID-19检测试剂盒
GenoSensor开发了一种高灵敏度检测方法,利用实时逆转录聚合酶链反应(RT-PCR) 直接检测病毒基因组(RNA),具有操作简便和可实时检测得特点。
| 货号 | 品名 | 产品描述 | 规格 |
| 2702-22 | GS™ COVID-19 Real-Time PCR Kit - 30 | Provide all-in-one master mix including cDNA synthesis, PCR mix, primers and probe of each gene. | 22 samples |
| 2702-94 | GS™ COVID-19 Real-Time PCR Kit - 126 | 94 samples |
● QS™ DNA 提取试剂盒
QS™ DNA 提取试剂盒包含的试剂能够裂解细胞、使蛋白质变性,并保护核酸免受核酸酶和氧化作用的降解。该方法极其快速且简单,只需两步操作,即可从多种类型的组织和细胞中提取 DNA,提取的可直接用于 PCR 和测序分析,无需纯化步骤。
| 货号 | 品名 | 产品描述 | 规格 |
| QS8001 | QS™ DNA Extraction kit | Solution A (Lysis)100ml and Solution B (Balance) | 10ml |
▎GenoSensor Corporation提供的服务
● 基因组改变分析:包括多态性基因分型(如SNPs和STRs)、基因组结构分析、基因扩增与缺失分析以及基因组重排分析。
● 定制微阵列:根据提供探针化学物质,构建经过质量控制的阵列。临床应用:专门为癌症和心血管疾病开发和销售基因产品。
● 靶标制备:例如从组织、培养物和微生物中分离和纯化基因组DNA、质粒DNA和RNA。
● 靶基因扩增、定量和标记:提供基因扩增、产物定量和靶标标记服务。
● 测序:基因测序使用ABI测序系统进行。

瑞士Kinematica AG是分散仪器设备中占主导地位的供应商之一,用户已遍布全世界的实验室、试验工厂以及生产应用中。Kinematica AG公司的产品包括运行容量小于0.1毫升的实验室分散单元,也有吞吐量达到300000升/小时的生产机器。所有这一切都是在直径3毫米到450毫米的定转子系统运转下完成的。这些单位最高可以达到的速度为50米/秒,这是当前市场上的最快速度,其剪切速率高达每秒300000次。除了定转子乳化机,Kinematica AG还提供切割打磨机,搅拌机,粘度计,温度和压力监测装置,以及执行所需应用程序所必要的附件。
Since our company’s founding in 1962, innovation has been a cornerstone of Kinematica’s development strategy.
Ever since our company’s founder, Professor Willems, revolutionized the industry with his rotor / stator invention, Kinematica has continued perfecting the technique by customizing and engineering its solutions to fit the most demanding applications. Our commitment to state-of-the-art technology has remained intact and been renewed decade after decade by achieving a de facto standard in several industries today, where our products are helping thousands of end users around the world.
«Homogenizing perfected» has been and will continue to be the focus of our efforts, in addition to the deeper integration of the technologies for a «connected world» where quality and performance without compromise will continue to represent the commitment to our customers. We look forward to having you be part of this exciting journey and sharing a bright future of mutual success.
主要产品系列:
POLYTRON® Immersion Dispersers
MEGATRON® Inline Dispersers for Production
MEGATRON® Inline Dispersers for Pilot Plants
REACTRON® Highly Scalable Reactors
BIOTRONA® Highly Turbulent Mixers
POLYMIX® Mills and Stirrers
MICROTRON® Mixers and Blenders
<更多详情请联系
艾美捷科技有限公司
全国服务热线:400-6800-868
邮箱:sales@amyjet.com
网站:www.amyjet.com
" data-original="http://eurofins.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="Kinematica AG"> Kinematica AG
艾美捷科技代理Phenomenex品牌。
Phenomenex致力于开发新型分析化学解决方案,以解决工业、临床研究、政府和学术实验室中研究人员的分离和纯化挑战。
一些特色产品包括:
(1)稳健的生物制剂分析:采用新型钛 BioTi™ 生物相容性硬件,可最大限度地减少引发,四个颗粒平台可实现最佳多功能性,九个颗粒化学成分可最大限度地提高选择性和灵敏度。
(2)低流失气相色谱分离:Phenomenex Zebron 气相色谱柱产品组合涵盖广泛的应用。从最简单到最具挑战性的方法,Phenomenex的气相色谱柱技术使Phenomenex能够提供高性能和更快的分析,并实现最复杂基质的最佳分离度和分离。
(3)将样品净化时间缩短 40%:Strata-X PRO 是一种新型创新的固相萃取 (SPE) 吸附剂,可提供更快、更清洁的样品萃取方法,彻底改变传统的 SPE 方法。Strata-X PRO 提供改进且耐用的聚合物吸附剂性能,并结合基质去除技术,提供革命性的解决方案。使用更快的 SPE 方法,可将 SPE 方案的时间至少缩短 40%。无需活化或平衡的更少步骤可创建快速的 SPE 方法,而不会失去 SPE 净化样品的重要性。
(4)在任何系统上均具有超高性能:与传统的全多孔介质相比,Kinetex Core-Shell 技术在效率上有了显着的提高,可用于提高分辨率、显著提高生产率、减少溶剂消耗并降低成本。无论运行的是高效液相色谱 (HPLC) 还是超高效液相色谱 (UHPLC) 方法,Kinetex 核壳系列都能提供出色的性能。Phenomenex设计、制造和销售自己的二氧化硅和有机二氧化硅核壳颗粒。
< " data-original="http://eurofins.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Phenomenex品牌"> 艾美捷科技代理Phenomenex品牌
艾美捷科技代理Revmab Bioscience品牌。
Revmab Bioscience是一家专注于单克隆抗体药物研发和生产的生物技术公司。公司致力于通过创新的生物技术手段,开发高效、安全的抗体药物,用于治疗自身免疫疾病和感染性疾病。Revmab Bioscience采用高效表达系统,确保抗体的高产量和高纯度;拥有先进的生产工艺和质量控制体系,确保产品的稳定性和一致性;同时具备创新研发能,能够快速开发新型抗体药物。
Revmab公司可提供的产品包括:
(1)单克隆抗体药物:提供多种单克隆抗体药物,用于癌症、自身免疫疾病和感染性疾病的治疗。
(2)生物类似药:开发和生产的生物类似药,用于多种疾病的治疗。
(3)抗体药物偶联物(ADC):提供抗体药物偶联物,用于靶向治疗癌症。
(4)定制抗体开发:根据客户需求,提供定制化的抗体开发服务。
<<< " data-original="http://eurofins.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Revmab Bioscience品牌"> 艾美捷科技代理Revmab Bioscience品牌

艾美捷科技代理Norgen Biotek品牌。
Norgen Biotek由Yousef Haj-Ahmad博士于1998年创立。Norgen是一家获得ISO 9001、ISO 13485和ISO 15189认证的全面集成生物技术公司,为科学界提供全面的研究服务,如下
一代测序、核酸提取。
Norgen Biotek公司的产品范围包括:RNA、DNA、外切体和蛋白质提取的样品采集,保存,提取和检测相关产品。
(1)样本采集和保存:用于采集和保存各种样本(包括血液、血浆、尿液、粪便、唾液)的设备等等。
(2)纯化和分离:使用 Norgen 易于使用的试剂盒分离和纯化高质量的 RNA、DNA、蛋白质、外泌体等。
(3)NGS 文库制备试剂盒:简单快速的工作流程,用于准备您的下一个小型文库RNA-seq、RNA-seq 和宏基因组学。
(4)分子诊断:使用 Norgen 的 PCR 和 RT-PCR Taqman 检测试剂盒针对多种病原体。还提供其他引物和探针。
(5)实验室组件:酶、缓冲液、试剂、无核酸酶水、塑料和过滤设备。
< " data-original="http://eurofins.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Norgen Biotek品牌"> 艾美捷科技代理Norgen Biotek品牌
艾美捷科技代理Berry & Associates全系列修饰核苷酸等
美国 Berry & Associates 公司成立于1989年,提供近200种亚磷酰胺和核苷酸合成用固相交联单体,以及数百种核苷、核苷酸、糖类、荧光标记物、淬灭剂和杂环化合物。
Founded in 1989 with roots in the nucleoside field, Berry & Associates soon moved into the chemistry of nucleic acids, resulting in a current portfolio of nearly 200 phosphoramidites and solid phase-linked monomers for oligonucleotide synthesis as well as hundreds of nucleosides, nucleotides, carbohydrates, spacers, fluorescent markers, quenchers, and heterocycles - all proudly made at our facility just outside of Ann Arbor, Michigan. Although our company is small, the credentials of our highly trained staff of chemists include over 400 publications and 80 patents in synthetic organic and medicinal chemistry. High quality chemicals, timeliness, and personalized service are the hallmarks of Berry & Associates.







Berry & Associates的主要产品包括:
| 产品名称 | 产品编号 | 纯度 | 规格 |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2'-3'-Dideoxyguanosine | PR 3505 | ≥95% | 25 mg; 100 mg |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 2',3'-Dideoxyuridine | PY 7278 | ≥97% | 100 mg; 500 mg |
| 2',3'-Didehydro-2',3'-dideoxyuridine | PY 7279 | ≥97% | 25 mg; 100 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| 2-Amino-2'-deoxyadenosine | PR 3060 | ≥97% | 1 g; 5 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-deoxyadenosine | PR 3080 | ≥95% | 100 mg; 1 g |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-isobutyryl-2'-deoxyadenosine | PR 3130 | ≥95% | 100 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2-(Dimethylaminomethylidene)amino-6-methoxylamino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3670 | ≥95% | 100 mg; 1 g |
| 2-Amino-9-(β-D-2'-deoxyribfuranosyl)purine | PR 3070 | ≥97% | 25 mg; 100 mg |
| 2-Amino-9-(2-O-methyl-β-D-ribofuranosyl)purine | PR 3160 | ≥97% | 100 mg; 250 mg |
| 2-Amino-9-(β-D-ribofuranosy)purine Hemihydrate | PR 3180 | ≥97% | 25 mg; 100 mg |
| 2-(Dimethylaminomethylidene)amino-9-(β-D-2-deoxyribofuranosyl)purine | PR 3680 | ≥97% | 100 mg; 1 g |
| 6-N-Acyl-6-N-methyl-2'-deoxyadenosine | PR 3006 | ≥95% | 25 mg; 100 mg |
| 8-Amino-2'-deoxyadenosine | PR 3115 | ≥97% | 10 mg; 100 mg |
| N6-(6-Aminohexyl)-2'-deoxyadenosine | PR 3120 | ≥90% | 100 mg; 1 g |
| 8-Azido-2'-deoxyadenosine | PR 3125 | ≥97% | 10 mg; 100 mg |
| N6-Benzoyl-8-benzyloxy-2'-deoxyadenosine | PR 3230 | ≥95% | 50 mg; 250 mg |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-8-oxo-2'-deoxyadenosine | PR 3260 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| 8-Benzyloxy-2'-deoxyadenosine | PR 3280 | ≥97% | 100 mg; 1 g |
| 8-Bromo-2'-deoxyadenosine | PR 3290 | ≥90% | 2 g; 10 g |
| 8-Bromo-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3320 | ≥95% | 100 mg; 1 g |
| 8-Bromo-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-2'-deoxyadenosine | PR 3340 | ≥97% | 0g (discontinued); |
| 2'-Deoxyadenosine Monohydrate | PR 3445 | ≥97% | 25 g; 100 g |
| 2',3'-Dideoxyadenosine | PR 3495 | ≥95% | 25 mg; 100 mg |
| 2-Fluoro-2'-deoxyadenosine | PR 3496 | ≥97% | 25 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| N6-Methyl-2'-deoxyadenosine | PR 3740 | ≥97% | 100 mg; 1 g |
| 4-Chloro-1-(2-deoxy-β-D-ribofuranosyl)-7-methyl-1H-imidazo[4,5-c]pyridine | PRA 10012 | ≥95% | 10 mg; 50 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| 7-(3-Nitrophenyl)-7-deaza-2'-deoxyadenosine | PRA 10032 | ≥95% | 10 mg; 50 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 8-Allyloxy-2'-deoxyguanosine | PR 3010 | ≥90% | 0Discontinued; |
| 8-Allyloxy-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3015 | ≥90% | 1 g; 10 g |
| 8-Allyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3020 | ≥90% | 1 g; 10 g |
| 5'-Azido-5'-deoxyguanosine | PR 3225 | ≥90% | 5 mg; 10 mg |
| 8-Benzyloxy-N2-isobutyryl-2'-deoxyguanosine | PR 3285 | ≥90% | 1 g; 10 g |
| 8-Bromo-2'-deoxyguanosine | PR 3300 | ≥90% | 1 g; 5 g |
| 8-Bromo-5'-O-(dimethyoxytrityl)-N2-(dimethyl-aminomethylidene)-2'-deoxyguanosine | PR 3310 | ≥97% | 500 mg; 1 g |
| 8-Bromo-N2-(dimethylaminomethylidene)-2'-deoxyguanosine | PR 3330 | ≥90% | 250 mg; 1 g |
| 5'-O-Dimethoxytrityl-N2-(dimethylaminomethylidene)-8-ethenyl-2'-deoxyguanosine | PR 3335 | ≥95% | 100 mg; 1 g |
| 2'-Deoxyguanosine monohydrate | PR 3452 | ≥97% | 10 g; 100 g |
| α-2'-Deoxyguanosine | PR 3455 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-ethyl-2'-deoxyguanosine | PR 3600 | ≥97% | 100 mg; 1 g |
| 3',5'-Di-O-acetyl-2'-deoxyguanosine | PR 3605 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-N2-methyl-2'-deoxy-guanosine | PR 3630 | ≥97% | 100 mg; 1 g |
| N2-Ethyl-2'-deoxyguanosine | PR 3700 | ≥95% | 25 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| N2-Isobutyl-2'-deoxyguanosine | PR 3745 | ≥97% | 10 mg; 100 mg |
| N1-Methyl-2'-deoxyguanosine | PR 3748 | ≥97% | 25 mg; 1 g |
| N2-Methyl-2'-deoxyguanosine | PR 3750 | ≥97% | 25 mg; 100 mg |
| O6-Methyl-2'-deoxyguanosine | PR 3755 | ≥90% | 5 mg; 25 mg |
| 6-Thio-2'-deoxyguanosine | PR 3845 | ≥97% | 10 mg; 100 mg |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 2-Amino-5'-O-(dimethoxytrityl)-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3090 | ≥97% | 250 mg; 1 g |
| 2-Amino-N6-(dimethylaminomethylidene)-N2-isobutyryl-2'-O-methyladenosine | PR 3110 | ≥95% | 250 mg; 1 g |
| 2-Amino-N2-O-methyladenosine | PR 3150 | ≥97% | 1 g; 10 g |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 2'-O-Methyladenosine | PR 3734 | ≥97% | 1 g; |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-thiouridine | PY 7575 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-O-methyl-4-(methylithio)uridine | PY 7577 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 5'-O-Acetyl-3'-azido-N2-palmitoyl-2',3'-dideoxy-guanosine | PR 3000 | ≥97% | 25 mg; 250 mg |
| 3'-Azido-N6-benzoyl-2',3'-dideoxyadenosine | PR 3200 | ≥90% | 50 mg; 250 mg |
| 3'-Azido-2',3'-dideoxyadenosine | PR 3210 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-2',3'-dideoxyguanosine | PR 3220 | ≥97% | 10 mg; 25 mg |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| N6-Benzoyl-3'-deoxyadenosine | PR 3240 | ≥97% | 100 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-3'-deoxyadenosine | PR 3250 | ≥97% | 100 mg; 1 g |
| 3'-Deoxyadenosine | PR 3430 | ≥97% | 10 mg; 100 mg |
| 3'-Deoxyguanosine | PR 3460 | ≥97% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-3'-deoxyguanosine | PR 3590 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-3'-deoxyguanosine | PR 3690 | ≥97% | 20 mg; 100 mg |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 5'-O-(Dimethoxytrityl)-5,6-dihydro-2'-deoxyuridine | PY 7230 | ≥97% | 100 mg; |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 2-Amino-6-chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3040 | ≥97% | 1 g; |
| 2-Amino-6-chloro-9-(3,5-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3045 | ≥95% | 1 g; |
| 2-Amino-6-chloro-9-(β-D-ribofuranosyl)purine | PR 3050 | ≥95% | 5 g; 25 g |
| 6-Chloro-9-(β-D-2-deoxyribofuranosyl)purine | PR 3370 | ≥97% | 100 mg; 1 g |
| 6-Chloro-9-(3,5-O-di-(p-toluoyl)-β-D-2-deoxyribofuranosyl)purine | PR 3380 | ≥90% | 100 mg; 1 g |
| 6-Chloro-9-(5-O-dimethoxytrityl-β-D-2-deoxyribofuranosyl)purine | PR 3390 | ≥97% | 0 g; |
| 6-Chloro-9-(β-D-ribofuranosyl)purine | PR 3400 | ≥97% | 5 g; 10 g |
| Adenosine | PR 3005 | ≥97% | 100 g; 1 kg |
| 8-Methyladenosine | PR 3007 | ≥95% | 25 mg; 100 mg |
| Vidarabine | PR 3008 | ≥97% | 1 g; 5 g |
| 2-Aminoadenosine (2,6-Diaminopurine riboside) | PR 3030 | ≥97% | 2 g; 10 g |
| N1-Methyladenosine hydroiodide | PR 3032 | ≥95% | 100 mg; 1 g |
| 2-Methyladenosine | PR 3035 | ≥97% | 10 mg; 25 mg |
| 5'-Chloro-5'-deoxyadenosine | PR 3360 | ≥97% | 100 mg; 1 g |
| N6-Methyladenosine | PR 3732 | ≥97% | 100 mg; 1 g |
| N6-Methyl-2'-O-Methyladenosine | PR 3733 | ≥97% | 50 mg; 100 mg |
| 3-Deaza-3-methyl-2'-deoxyadenosine | PRA 10013 | ≥97% | 10 mg; 25 mg |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 2-Amino-4-chloro-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10000 | ≥97% | 100 mg; 1 g |
| 2-Amino-4-methoxy-7-(β-D-2-deoxyribofuranosyl)pyrrolo[2,3-d]pyrimidine | PRA 10005 | ≥97% | 500 mg; 1 g |
| 4-Chloro-1-(β-D-2-deoxyribofuranosyl)imidazo[4,5-C]pyridine | PRA 10006 | ≥90% | 25 mg; 100 mg |
| 8-Azaadenosine | PRA 10007 | ≥97% | 20 mg; |
| 8-Aza-7-deaza-2'-deoxyadenosine (4-Amino-1-(2-deoxyribofuranosyl)pyrazolo[3,4-d]-pyrimidine) | PRA 10008 | ≥95% | 10 mg; 100 mg |
| 4-Chloro-1-(3,5-di-O-toluoyl-2-deoxy-β-D-ribofuranosyl)pyrazolo[3,4-d]pyrimidine | PRA 10009 | ≥95% | 100 mg; 1 g |
| N6-Benzoyl-7-deaza-2'-deoxyadenosine | PRA 10010 | ≥97% | 100 mg; 1 g |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; 1 g |
| 5'-O-Dimethoxytrityl-N6-(N,N-dimethylaminomethylene)-8-aza-7-deaza-2'-deoxyadenosine | PRA 10019 | ≥97% | 500 mg; 1 g |
| N6-Benzoyl-5'-O-(dimethoxytrityl)-7-deaza-2'-deoxyadenosine | PRA 10020 | ≥97% | 100 mg; 1 g |
| 3-Deaza-2'-deoxyadenosine | PRA 10025 | ≥97% | 25 mg; 100 mg |
| 7-Deaza-2'-deoxyadenosine | PRA 10030 | ≥97% | 100 mg; 1 g |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; 100 mg |
| 5-Iodo-2'-deoxytubercidin | PRA 10036 | ≥95% | 10 mg; 50 mg |
| 7-Deaza-2'-deoxyguanosine | PRA 10040 | ≥97% | 100 mg; 1 g |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 7-Deaza-2'-deoxyxanthosine | PRA 10050 | ≥97% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-7-deaza-2'-deoxyxanthosine | PRA 10055 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-N2-(dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10100 | ≥97% | 100 mg; 1 g |
| N2-(Dimethylaminomethylidene)-7-deaza-2'-deoxyguanosine | PRA 10110 | ≥97% | 100 mg; 1 g |
| Sangivamycin | PRA 10140 | ≥97% | 10 mg; 25 mg |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; 100 mg |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| dNaM | FC 8110 | ≥97% | 25 mg; 100 mg |
| 9-Deaza-2'-deoxyguanosine | PRA 10120 | ≥97% | 10 mg; 100 mg |
| 9-Deazaguanosine | PRA 10130 | ≥97% | 10 mg; 100 mg |
| 2-Chloro-6-(β-D-2-deoxyribofuranosyl)-3,5-diaminopyrazine | PYA 11000 | ≥97% | 10 mg; 25 mg |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| 2'-Deoxypseudoisocytidine | PYA 11005 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudouridine | PYA 11010 | Purity: ≥97% | 25 mg; |
| 5'-O-(Dimethoxytrityl)-N-(dimethylamino) methylidene-2'-deoxypseudoisocytidine | PYA 11035 | Purity: ≥97% | 50 mg; 100 mg |
| 1,3-Dimethyl-2'-deoxypseudouridine | PYA 11040 | ≥97% | 10 mg; 100 mg |
| 1,3-Dimethylpseudouridine | PYA 11050 | ≥97% | 10 mg; 50 mg |
| N1-Methylpseudouridine | PYA 11052 | ≥95% | 10 mg; 50 mg |
| N3-Methylpseudouridine | PYA 11054 | ≥97% | 10 mg; 25 mg |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Pseudoisocytidine hydrochloride | PYA 11060 | ≥97% | 10 mg; 100 mg |
| Pseudothymidine | PYA 11070 | ≥97% | 10 mg; 100 mg |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; 50 mg |
| 3'-O-(t-Butyldimethylsilyl)-5'-oxo-2'-deoxy-8,5'-cycloadenosine | PR 3350 | ≥97% | 10 mg; |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-Deoxy-8,5'-cycloadenosine | PR 3440 | ≥97% | 10 mg; 100 mg |
| 2',5'-Dideoxy-8,5'-cycloadenosine | PR 3500 | ≥97% | 10 mg; |
| 2',3'-O-Isopropylidene-5'-oxo-8,5'-cycloadenosine | PR 3730 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-8,5'-cycloadenosine | PR 3800 | ≥97% | 10 mg; 100 mg |
| 5'-Oxo-2'-deoxy-8,5'-cycloadenosine | PR 3810 | ≥97% | 10 mg; |
| N4-Acetyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7010 | ≥95% | 0 g DISCONTINUED; |
| N4-Acetyl-5'-methyl-2'-O-methylcytidine | PY 7020 | ≥97% | 0 g DISCONTINUED; |
| N4-Benzoyl-5-(furan-2-yl)-2'-deoxycytidine | PY 7054 | ≥97% | 25 mg; 100 mg |
| N4-Benzoyl-3'-deoxycytidine | PY 7080 | ≥97% | 20 mg; 100 mg |
| N4-Benzoyl-5'-O-(dimethoxytrityl)-5-methyl-2'-O-methylcytidine | PY 7100 | ≥95% | 100 mg; 1 g |
| N4-Benzoyl-2'-O-methylcytidine | PY 7110 | ≥97% | 500 mg; 1 g |
| 5-Bromo-2'-deoxycytidine | PY 7115 | ≥97% | 1 g; 10 g |
| Cytidine | PY 7215 | ≥97% | 50 g; 500 g |
| 2'-Deoxycytidine | PY 7216 | ≥97% | 10 g; 50 g |
| 2'-Deoxycytidine Hydrochloride | PY 7217 | ≥97% | 5 g; 50 g |
| 5'-Azido-2',5'-dideoxycytidine | PY 7219 | ≥97% | 25 mg; 100 mg |
| 3'-Deoxycytidine | PY 7220 | ≥97% | 20 mg; 100 mg |
| N4-Ethyl-2'-deoxycytidine | PY 7245 | ≥97% | 100 mg; 250 mg |
| 5-Methyl-2'-deoxyisocytidine | PY 7255 | ≥95% | 500 mg; 1 g |
| 6-(β-D-2-Deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7270 | ≥97% | 20 mg; 50 mg |
| 2',3'-Dideoxycytidine | PY 7325 | ≥95% | 50 mg; 100 mg |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-iodo-2'-O-methylcytidine | PY 7350 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-O-methylcytidine | PY 7360 | ≥97% | 0 DISCONTINUED; |
| N4-(Diisobutylaminomethylidene)-5-iodo-2'-O-methylcytidine | PY 7370 | ≥97% | 0 DISCONTINUED; |
| 6-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido-[4,5-c][1,2]oxazin-7-one | PY 7380 | ≥97% | 50 mg; |
| N4-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-5-(1-propynyl)-2'-deoxycytidine | PY 7400 | ≥97% | 100 mg; 500 mg |
| 5-O-(Dimethoxytrityl)-N4-dimethylaminomethylidene-5-iodo-2'-deoxycytidine | PY 7410 | ≥97% | 100 mg; |
| 6-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-3,4-dihydro-8H-pyrimido[4,5-c][1,2]oxazin-7-one | PY 7540 | ≥95% | 250 mg; 500 mg |
| Cytidin-5-yl-methanesulfonate sodium salt hydrate | PY 7586 | ≥95% | 50 mg; 100 mg |
| 5-[(2-Cyanoethoxy)methyl]-2'-deoxycytidine | PY 7587 | ≥97% | 10 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxycytidine | PY 7588 | ≥97% | 50 mg; 100 mg |
| 5-Formyl-2'-deoxycytidine | PY 7589 | ≥97% | 5 mg; 10 mg |
| 5-Carboethoxy-2'-deoxycytidine | PY 7592 | ≥95% | 25 mg; 100 mg |
| 2'-Deoxycytidine-5-carboxylic acid, sodium salt | PY 7593 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxymethylcytidine | PY 7596 | ≥97% | 50 mg; 100 mg |
| Cytidine-5-carboxylic acid, sodium salt | PY 7598 | ≥97% | 10 mg; 50 mg |
| 5-Formylcytidine | PY 7599 | ≥97% | 5 mg; 10 mg |
| 5-Iodo-2'-deoxycytidine | PY 7607 | ≥97% | 2 g; 10 g |
| 5-Iodocytidine | PY 7609 | ≥97% | 5 g; |
| 5-Iodo-2'-O-methylcytidine | PY 7620 | ≥90% | 20 mg; 100 mg |
| 5-Methyl-2'-deoxycytidine Hydrochloride | PY 7635 | ≥97% | 0.25 g; 1 g |
| 2'-O-Methylcytidine | PY 7636 | ≥97% | 1 g; 5 g |
| 5-Methylcytidine | PY 7637 | ≥97% | 1 g; 5 g |
| N4-Methylcytidine | PY 7638 | ≥97% | 25 mg; 100 mg |
| 5-Methyl-2'-O-methylcytidine | PY 7640 | ≥97% | 100 mg; 500 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| 5-(1-Propynyl)-2'-O-methylcytidine | PY 7660 | ≥95% | 10 mg; 50 mg |
| 5-(1-Propynyl)-2'-deoxycytidine | PY 7700 | ≥90% | 5 mg; 10 mg |
| 2-Thiocytidine | PY 7721 | ≥97% | 10 mg; 100 mg |
| 2-Thio-2'-deoxycytidine | PY 7723 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| N6-Benzoyl-8-oxo-2'-deoxyadenosine | PR 3270 | ≥97% | 100 mg; 1 g |
| (5'S)-8,5'-Cycloadenosine | PR 3410 | ≥97% | 10 mg; 100 mg |
| (5'S)-2'-Deoxy-8,5'-cycloadenosine | PR 3420 | ≥97% | 10 mg; |
| 5'-O-(Dimethoxytrityl)-8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3610 | ≥97% | 100 mg; 1 g |
| 8-Oxo-2'-deoxyadenosine | PR 3705 | ≥95% | 25 mg; 250 mg |
| 8-Oxo-2'-deoxyguanosine | PR 3710 | ≥97% | 25 mg; 250 mg |
| 8-Oxo-N2-isobutyryl-2'-deoxyguanosine | PR 3720 | ≥90% | 100 mg; 1 g |
| 8-Hydroxyguanosine | PR 3795 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 5-Aza-2'-deoxycytidine | PY 7105 | ≥95% | 25 mg; 100 mg |
| 5,6-Dihydro-5-aza-2'-deoxycytidine | PY 7106 | ≥97% | 25 mg; 100 mg |
| 5,6-Dihydro-2'-deoxyuridine | PY 7330 | ≥97% | 100 mg; |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| 5-Hydroxy-2'-deoxycytidine | PY 7595 | ≥95% | 25 mg; 250 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 6-Methylcytidine | PY 7641 | ≥97% | 10 mg; 25 mg |
| Nap-dU | PY 7735 | ≥97% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 3,N4-Etheno-2'-deoxycytidine | PYA 11130 | ≥97% | 100 mg; 500 mg |
| Pyrrolo-dC | PYA 11090 | ≥95% | 10 mg; 100 mg |
| 6-Methyl-3-(β-D-2-ribofuranosyl)pyrrolo[2,3-d]pyrimidin-2-one | PYA 11092 | ≥97% | 10 mg; 100 mg |
| 3-(5'-O-Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-6-methylpyrrolo[2,3-d]pyrimidin-2-one | PYA 11095 | ≥95% | 100 mg; 1 g |
| 3-(2'-Deoxy-β-D-2-ribofuranosyl)pyrido[2,3-d]pyrimidine-2,7(8H)-dione | PYA 11100 | ≥95% | 10 mg; 100 mg |
| 8-18O-Hydroxyguanosine | IOPR 3795 | ≥95% | 2 mg; 5 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| 5'-O-Dimethoxytrityl-N2-(trifluoroacetamido)hexyl-2'-deoxyguanosine | PR 3701 | ≥95% | 25 mg; 100 mg |
| N2-Dimethylguanosine | PR 3702 | ≥97% | 10 mg; 100 mg |
| Guanosine | PR 3703 | ≥97% | 100 g; 500 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| O6-Methylguanosine | PR 3757 | ≥97% | 25 mg; 100 mg |
| 2'-O-Methylguanosine | PR 3760 | ≥97% | 1 g; 10 g |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 8-Bromoguanosine | PR 3796 | ≥97% | 0 g; |
| 8-Benzyloxyguanosine | PR 3797 | ≥95% | 100 mg; 1 g |
| 7-Methyl-7-deaza-2'deoxyguanosine | PRA 10042 | ≥97% | 10 mg; 50 mg |
| 7-Deazaguanosine | PRA 10045 | ≥97% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 2'-Deoxypseudoguanosine | PRA 10103 | ≥97% | 10 mg; 50 mg |
| 2'-Deoxypseudoisoguanosine | PRA 10104 | ≥97% | 10 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-5-nitroindole | PRA 10060 | ≥97% | 100 mg; 1 g |
| 1-(β-D-2-Deoxyribofuranosyl)-4-methylindole | PRA 10070 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-4-methylindole | PRA 10080 | ≥97% | 0 g; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-5-nitroindole | PRA 10090 | ≥97% | 100 mg; 1 g |
| 2'-Deoxy-4-desmethylwyosine | PR 3450 | ≥95% | 100 mg; 500 mg |
| 2'-Deoxyinosine | PR 3463 | ≥97% | 10 g; 100 g |
| 5'-Azido-2',5'-dideoxyinosine | PR 3464 | ≥97% | 5 mg; 25 mg |
| 3',5'-Di-O-acetyl-2'-deoxyinosine | PR 3480 | ≥97% | 1 g; |
| 3',5'-Di-O-acetyl-O6-phenyl-2'-deoxyinosine | PR 3490 | ≥90% | 1 g; |
| 5'-O-(Dimethoxytrityl)-2'-O-methylinosine | PR 3640 | ≥97% | 1 g; |
| 5'-O-(Dimethoxytrityl)-O6-phenyl-2'-deoxyinosine | PR 3660 | ≥97% | 100 mg; 1 g |
| Inosine | PR 3725 | ≥97% | 100 g; 500 g |
| 2',3'-Dideoxyinosine | PR 3727 | ≥97% | 100 mg; 1 g |
| 2'-O-Methylinosine | PR 3770 | ≥97% | 500 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| O6-Phenyl-2'-deoxyinosine | PR 3840 | ≥97% | 100 mg; 1 g |
| 2-Fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3842 | ≥97% | 25 mg; |
| 5'-O-Dimethoxytrityl-2-fluoro-6-O-(2-(4-nitrophenyl)ethyl)-2'-deoxyinosine | PR 3843 | ≥90% | 25 mg; 100 mg |
| 2'-Deoxyisoguanosine | PR 3465 | ≥97% | 10 mg; 100 mg |
| N6-(Diisobutylaminomethylidene)-2'-deoxyisoguanosine | PR 3510 | ≥90% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-5'-O-(dimethoxytrityl)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3520 | ≥95% | 100 mg; 1 g |
| N6-(Diisobutylaminomethylidene)-O2-(diphenylcarbamoyl)-2'-deoxyisoguanosine | PR 3530 | ≥90% | 100 mg; 1 g |
| Isoguanosine | PR 3735 | ≥97% | 10 mg; 50 mg |
| d5SICS | FC 8120 | ≥97% | 25 mg; 100 mg |
| AICA Riboside (AICAR) | MN 20001 | ≥97% | 0 g (DISCONTINUED); |
| 2',3'-Di-O-methyladenosine | PR 3540 | ≥97% | 100 mg; 1 g |
| 2,6-Bis-O-[2-(4-nitrophenyl)ethyl]-2'-deoxyxanthosine | PR 3692 | ≥95% | 10 mg; 100 mg |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; 100 mg |
| 8-Aza-7-deaza-2'-deoxyguanosine | PRA 10170 | ≥95% | 10 mg; 100 mg |
| 6-Amino-2-(2-deoxy-β-D-ribofuranosyl)-2,5-dihydro-4H-pyrazolo-[3,4-d]-pyrimidin-4-one | PRA 10175 | ≥95% | 10 mg; 100 mg |
| 3'-Deoxy-3',4'-didehydrocytidine | PY 7790 | ≥95% | 10 mg; 25 mg |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| tC Nucleoside | PYA 11110 | ≥97% | 50 mg; 100 mg |
| tCnitro Nucleoside | PYA 11115 | ≥95% | 5 mg; 25 mg |
| 2'-Deoxynebularine | PR 3470 | Purity: ≥97% | 100 mg; 1 g |
| 7-Methylinosine | PR 3780 | ≥95% | 100 mg; 250 mg |
| 7-Methyl-6-thioguanosine | PR 3790 | ≥75% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-3-nitropyrrole | PYA 11020 | ≥97% | 50 mg; |
| 1-(5-O-(Dimethoxytrityl)-β-D-2-deoxyribofuranosyl)-3-nitropyrrole | PYA 11030 | ≥95% | 100 mg; |
| Showdomycin | PYA 11056 | ≥97% | 10 mg; |
| Formycin A | PYA 11001 | ≥97% | 10 mg; |
| Formycin B | PYA 11002 | ≥97% | 10 mg; |
| Pseudouridine | PYA 11080 | ≥97% | 10 mg; |
| Pyrazofurin | PYA 11004 | ≥97% | 10 mg; |
| Toyocamycin | PRA 10150 | ≥97% | 10 mg; |
| 7-Deazaadenosine (tubercidin) | PRA 10035 | ≥97% | 10 mg; |
| Allopurinol riboside | PRA 10011 | ≥97% | 25 mg; |
| 5-Iodotubercidin | PRA 10095 | ≥90% | 5 mg; |
| Triciribine | PRA 10160 | ≥97% | 10 mg; |
| Tricyclic Nucleoside Phosphate | PRA 10162 | ≥95% | 10 mg; |
| 5-Amino-3-β-D-ribofuranosylthiazolo[4,5-d]pyrimidin-2,7(3H,6H)-dione | PRA 10047 | ≥97% | 10 mg; |
| 5'-Amino-5'-deoxythymidine | PY 7030 | ≥97% | 25 mg; 50 mg |
| O2,5'-Anhydrothymidine | PY 7060 | ≥95% | 500 mg; 1 g |
| 3'-Azido-3'-deoxythymidine (AZT) | PY 7065 | ≥97% | 500 mg; 1 g |
| 5'-Azido-5'-deoxythymidine | PY 7070 | ≥97% | 25 mg; 100 mg |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| 3'-O-(t-Butyldimethylsilyl)-5'-deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7120 | ≥97% | 1 g; |
| 3'-O-(t-Butyldimethylsilyl)thymidine | PY 7130 | ≥95% | 500 mg; 1 g |
| 5'-O-(t-Butyldimethylsilyl)thymidine | PY 7140 | ≥97% | 5 g; 10 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)thymidine | PY 7150 | ≥97% | 1 g; 5 g |
| 3',5'-bis-O-(t-Butyldimethylsilyl)-O4-(2,4,6-triisopropylphenylsulfonyl)thymidine | PY 7160 | ≥95% | 100 mg; 500 mg |
| S4-(2-Cyanoethyl)-5'-O-(dimethoxytrityl)-4-thiothymidine | PY 7200 | ≥95% | 10 mg; 100 mg |
| S4-(2-Cyanoethyl)-4-thiothymidine | PY 7210 | ≥95% | 10 mg; 100 mg |
| 5'-Deoxy-5'-(1,3-diphenyl-2-imidazolidinyl)thymidine | PY 7250 | ≥97% | 1 g; |
| 3'-Deoxythymidine | PY 7277 | ≥95% | 50 mg; 100 mg |
| 1-(3,5-Di-O-acetyl-β-D-deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)-5-methylpyrmidin-2-one | PY 7315 | ≥90% | 1 g; 10 g |
| 2',3'-Didehydro-3'-deoxythymidine | PY 7328 | ≥95% | 10 mg; 100 mg |
| (5S)-5,6-Dihydrothymidine | PY 7340 | ≥97% | 20 mg; 100 mg |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| (5S)-5'-O-(Dimethoxytrityl)-5,6-dihydrothymidine | PY 7390 | ≥97% | 100 mg; |
| 5'-O-(Dimethoxytrityl)-N3/O4-(toluoyl)-2-thiothymidine | PY 7510 | ≥97% | 50 mg; 100 mg |
| 2-O-Ethylthymidine | PY 7561 | ≥97% | 500 mg; 1 g |
| 5'-Iodo-5'-deoxythymidine | PY 7610 | ≥97% | 250 mg; 1 g |
| 5'-O-Methylthymidine | PY 7680 | ≥95% | 50 mg; 100 mg |
| 2-Thiothymidine | PY 7725 | ≥95% | 20 mg; 100 mg |
| Thymidine | PY 7727 | ≥97% | 25 g; 250 g |
| 5'-O-(p-Toluenesulfonyl)thymidine | PY 7740 | ≥97% | 5 g; |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5'-Trifluoroacetamido-5'-deoxythymidine | PY 7750 | ≥97% | 50 mg; |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 6-Azathymidine | PYA 11058 | ≥95% | 25 mg; 100 mg |
| NPOM-Caged-dT CEP | BA 0317 | ≥95% | 100 µmol; 0.25 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 3'-Azido-3'-deoxy-5'-O-methylthymidine | PY 7075 | ≥97% | 0 g DISCONTINUED; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| (5S,6R)-5',6'-Cyclo-5'-deoxy-5,6-dihydrothymidine | PY 7345 | ≥95% | 10 mg; 25 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 3-(2-Cyanoethyl)thymidine | PY 7742 | ≥95% | 10 mg; 25 mg |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| NPOM-Caged deoxythymidine | PY 7795 | ≥97% | 25 mg; 100 mg |
| 6-Methyl-3-(β-D-2-deoxyribofuranosyl)furano-[2,3-d]pyrimidin-2-one | PYA 11055 | ≥97% | 5 mg; 25 mg |
| 5-Ethynyl uridine CEP | BA 0353 | ≥90% | 100 µmol; 0.25 g |
| 2'-O-Acetyl-5'-O-benzoyl-5-methyl-3'-deoxyuridine | PY 7000 | ≥97% | 500 mg; 1 g |
| 5-[N-(2-Aminoethyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7040 | ≥97% | 100 mg; 1 g |
| 5-[N-(6-Aminohexyl)-3-(E)-acrylamido]-5'-O-(dimethoxytrityl)-2'-deoxyuridine | PY 7050 | ≥90% | 100 mg; 1 g |
| 5-(Furan-2-yl)-2'-deoxyuridine | PY 7053 | ≥97% | 25 mg; 100 mg |
| 1-(β-D-2-Deoxyribofuranosyl)-4-(1,2,4-triazol-1-yl)pyrimidin-2-one | PY 7055 | ≥97% | 20 mg; 100 mg |
| 5-Bromo-2'-deoxyuridine | PY 7117 | ≥97% | 10 g; 25 g |
| 5-Bromouridine | PY 7118 | ≥95% | 5 g; |
| (E)-5-(2-Carbomethoxyvinyl)-2'-deoxyuridine | PY 7170 | ≥97% | 1 g; |
| (E)-5-(2-Carbomethoxyvinyl)uridine | PY 7172 | ≥97% | 25 mg; 250 mg |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine | PY 7180 | ≥97% | 500 mg; 1 g |
| (E)-5-(2-Carboxyvinyl)uridine | PY 7185 | ≥97% | 1 g; |
| (E)-5-(2-Carboxyvinyl)-2'-deoxyuridine N-Hydroxysuccinimide Ester | PY 7190 | ≥97% | 100 mg; 1 g |
| S4-(2-Cyanoethyl)-4-thio-2'-deoxyuridine | PY 7212 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-3'-deoxyuridine | PY 7240 | ≥95% | 25 mg; 100 mg |
| 5-Methyl-3'-deoxyuridine | PY 7260 | ≥95% | 20 mg; 50 mg |
| 2'-Deoxyuridine | PY 7275 | ≥97% | 25 g; 100 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-deoxyuridine | PY 7280 | ≥95% | 100 mg; 500 mg |
| 3'-Azido-2',3'-dideoxy-5-bromouridine | PY 7286 | ≥97% | 10 mg; 50 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7290 | ≥95% | 500 mg; 1 g |
| 3',5'-Di-O-acetyl-5-fluoro-2'-O-methyluridine | PY 7300 | ≥97% | 50 mg; 250 mg |
| 3',5'-Di-O-acetyl-5-fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7310 | ≥97% | 20 mg; 50 mg |
| 3',5'-Di-O-benzoyl-5-fluoro-2'-O-methyluridine | PY 7320 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-fluoro-2'-O-methyluridine | PY 7420 | ≥95% | 100 mg; 500 mg |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-deoxyuridine | PY 7450 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-iodo-2'-O-methyluridine | PY 7460 | ≥97% | 50 mg; 100 mg |
| 5-Methoxymethyl-2'-deoxyuridine | PY 7465 | ≥95% | 10 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-methyl-2'-O-methyluridine | PY 7470 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-2'-O-methyluridine | PY 7480 | ≥97% | 500 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-deoxyuridine | PY 7490 | ≥95% | 50 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-(1-propynyl)-2'-O-methyluridine | PY 7500 | ≥95% | 25 mg; 100 mg |
| 5'-O-(Dimethoxytrityl)-5-[N-(2-(trifluoroacetamido)ethyl)-3-(E)acrylamido]-2'-deoxyuridine | PY 7520 | ≥97% | 100 mg; 1 g |
| 5'-O-(Dimethoxytrityl)-5-[N-(6-(trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7530 | ≥97% | 100 mg; 1 g |
| 1-(3,5-Di-O-(p-toluoyl)-β-D-2-deoxyribofuranosyl)-5-(2-(phthalimidooxy)ethyl)-4-(1,2,4-triazol-1-yl)-lH-pyrimidin-2-one | PY 7550 | ≥95% | 100 mg; 1 g |
| 3',5'-Di-O-(p-toluoyl)-5-(2-hydroxyethyl)-2'-deoxyuridine | PY 7560 | ≥95% | 500 mg; 1 g |
| 5-Ethynyl-2'-deoxyuridine | PY 7562 | ≥97% | 25 mg; 100 mg |
| 5-Ethynyl uridine | PY 7563 | ≥97% | 10 mg; 100 mg |
| 5-Fluoro-2'-deoxyuridine | PY 7565 | ≥97% | 100 mg; 1 g |
| 5-Fluoro-2'-O-methyluridine | PY 7570 | ≥97% | 50 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-deoxyuridine | PY 7580 | ≥97% | 25 mg; 100 mg |
| 5-Fluoro-O4-(2,4,6-trimethylphenyl)-2'-O-methyluridine | PY 7590 | ≥95% | 25 mg; 100 mg |
| 5-Hydroxy-2'-deoxyuridine | PY 7597 | ≥95% | 25 mg; 250 mg |
| 5-(2-Hydroxyethyl)-2'-deoxyuridine | PY 7600 | ≥95% | 25 mg; 50 mg |
| 5-Acetoxymethyl-2'-deoxyuridine | PY 7604 | ≥97% | 25 mg; 100 mg |
| 5-Hydroxymethyl-2'-deoxyuridine | PY 7605 | ≥95% | 25 mg; 250 mg |
| 2'-Fluoro-5'-iodo deoxyuridine | PY 7612 | ≥95% | 100 mg; |
| 5-Iodo-2'-deoxyuridine | PY 7615 | ≥97% | 10 g; 25 g |
| 5-Iodo-2'-O-methyluridine | PY 7630 | ≥97% | 100 mg; 1 g |
| 5-Iodouridine | PY 7632 | ≥95% | 5 g; 25 g |
| 5-Methyl-2'-O-methyluridine | PY 7650 | ≥97% | 100 mg; 1 g |
| 5-(1-Propynyl)-2'-O-methyluridine | PY 7670 | ≥97% | 10 mg; 25 mg |
| 2'-O-Methyluridine | PY 7690 | ≥97% | 5 g; |
| 3-Methyluridine | PY 7694 | ≥97% | 25 mg; 100 mg |
| 5-Methyluridine | PY 7695 | ≥97% | 200 mg; 1 g |
| 5-(1-Propynyl)-2'-deoxyuridine | PY 7710 | ≥97% | 100 mg; 1 g |
| 5-(Propargyloxy)-2'-deoxyuridine | PY 7712 | ≥95% | 10 mg; 100 mg |
| Zebularine | PY 7715 | ≥97% | 10 mg; 25 mg |
| 3',5'-O-(1,1,3,3-Tetraisopropyl-1,3-disiloxanediyl)-2'-deoxyuridine | PY 7720 | ≥90% | 500 mg; 1 g |
| 2-Thiouridine | PY 7724 | ≥97% | 25 mg; 100 mg |
| 5'-O-(p-Toluenesulfonyl)-2'-deoxyuridine | PY 7730 | ≥97% | 1 g; 5 g |
| 5-[3-(Trifluoroacetamido)-E-1-propenyl]-2’-deoxyuridine | PY 7754 | ≥95% | 100 mg; 1 g |
| 5-[3-(Trifluoroacetamido)-1-(E)-propenyl]uridine | PY 7758 | ≥97% | 100 mg; 1 g |
| 5-[N(2-(Trifluoroacetamido)ethyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7760 | ≥90% | 100 mg; 1 g |
| 5-[N(6-(Trifluoroacetamido)hexyl)-3-(E)-acrylamido]-2'-deoxyuridine | PY 7770 | ≥95% | 100 mg; 1 g |
| 5-[N-(6-(Trifluoracetamido)hexyl)-(E)-acrylamido]uridine | PY 7775 | ≥97% | 100 mg; 1 g |
| Uridine | PY 7780 | ≥97% | 100 g; 500 g |
| 2'3'-O-Isopropylidene uridine | PY 7781 | ≥97% | 5 g; 25 g |
| 5-Hydroxymethyl uridine | PY 7782 | ≥97% | 50 mg; 100 mg |
| 5-Methoxyuridine | PY 7783 | ≥97% | 10 mg; 50 mg |
| 6-Aza-2'-deoxyuridine | PYA 11057 | ≥95% | 50 mg; 100 mg |
" data-original="http://eurofins.51antibodies.com/template/company/xys_lvse/skin/image/lazyLoad.jpg" alt="艾美捷科技代理Berry & Associates全系列修饰核苷酸"> 艾美捷科技代理Berry & Associates全系列修饰核苷酸
<艾美捷科技代理Helvetica Health Care品牌全系列产品
Helvetica Health Care是一家位于瑞士日内瓦的医疗保健公司,致力于通过创新的产品和技术来管理健康和提高生活质量。作为瑞士生物技术协会的成员,Helvetica Health Care通过了ISO 13485认证,在质量和创新方面坚持最高标准。涵盖各种质量控制和验证面板,适用于不同的分子测试平台和检测。这些产品有多种规格,可用于单一或多种分析物的检测,帮助实验室监控测试性能,确保测试的准确性和可靠性。其质量控制和验证组合可根据产品配置、填充量和分析物浓度进行定制,满足不同平台的需求。
▎Helvetica Health Care产品线
Helvetica Health Care公司的产品涵盖:抗体、生命科学产品、血液分离产品、临床/诊断样本、质控品与标准品、分子生物学产品、细胞因子与生长因子、ELISA试剂盒/Western印迹相关产品、微生物、氧化应激产品、诊断产品以及人血浆制品。

▎Helvetica Health Care部分产品列表
| 货号 | 产品描述 |
| NATFRC-6C | NATtrol Flu/RSV/SARS-CoV-2 Positive Control (6 x 0.5mL) |
| NATCV9-6C | NATtrol Flu/RSV/SARS-CoV-2 Negative Control (6 x 0.5mL) |
| NATRPC2.1-BIO | NATtrol Respiratory Panel 2.1 (RP2.1) Controls (12 x 0.3mL) |
| NATRVP2.1-BIO | NATtrol Respiratory Verification Panel 2.1 (24 x 0.6mL) (EA) |
| NATRVP2.1-BIO Plus | NATtrol Respiratory Verification Panel 2 Plus (+NATCOV(MR)-BIO) (24x 0.6 ml + 1x 0.6 ml) |
| NATRVP2-QIA | NATtrol Respiratory Verification Panel 2 (21 x 0.25mL) (EA) |
| NATSARS(COV2)-VP | NATtrol SARS-CoV-2 Variant Panel (4 x 0.5mL) |
| NATSARS(COV2)-ERC | SARS-Related Coronavirus 2 (SARS-CoV-2) External Run Control (6 x 0.5 mL) |
| NATSARS(COV2)-ERC1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Positive Control (6x 1.0 ml) |
| NATSARS(COV2)-NEG | SARS-Related Coronavirus 2 (SARS-CoV-2) Negative Control (6 x 0.5 mL) |
| NATSARS(COV2)-NEG1 | NATtrol SARS-Related Coronavirus 2 (SARS-COV-2) Negative Control (6x 1.0 ml) |
| NATSARS(COV2)-ST | SARS-Related Coronavirus 2 (SARS-CoV-2) Stock |
| NATSARS(COV2-SA)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.351 Stock (1mL) |
| NATSARS(COV2-UK)-ST | NATtrol SARS-Related Coronavirus 2 (SARS-CoV-2) Variant B.1.1.7 Stock (1mL) |
| 0810229-0.5mg | Coronavirus 229E Lysate (0.5 mg) |
| 0810587 | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (1 mg) |
| 0810587-0.5mg | SARS-CoV-2 (Isolate: USA-WA1/2020) Lysate (0.5 mg) |
| 0810587CFHI-0.5mL | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (0.5 mL) |
| 0810587CFHI | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (Heat Inactivated) (1.0 mL) |
| 0810587UV | SARS-CoV-2 (Isolate: USA-WA1/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810589CFHI | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810589UV | SARS-CoV-2 (Isolate: Italy-INMI1) Culture Fluid (UV Inactivated) (1 mL) |
| 0810590CFHI | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810590UV | SARS-CoV-2 (Isolate: Hong Kong/VM20001061/2020) Culture Fluid (UV Inactivated) (1 mL) |
| 0810617UV | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) Culture Fluid (UV)) |
| 0810618UV | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) Culture Fluid (UV) |
| 0810619UV | SARS-CoV-2 Iso1 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810620UV | SARS-CoV-2 Iso2 Lin B.1.526_2021 Iota (NY-Wadsworth-21025952-01/2021) CF (UV Inactivated) |
| 0810621UV | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) CF (UV Inactivated) |
| 0810622UV | SARS-CoV-2 Lineage B.1.595_2020 (NY-Wadsworth-33126-01/2020) CF (UV Inactivated) |
| 0810612CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:USA/CA_CDC_5574/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810612UV | SARS-CoV-2 Lineage B.1.1.7; Alpha Variant (USA/CA_CDC_5574/2020) CF (UV Inactivated) (1 mL) |
| 0810613CFHI | SARS-CoV-2 Variant B.1.351(Isolate:South_Africa/KRISP-K005325/2020) CF (Heat Inactivated) (1 mL) |
| 0810613UV | SARS-CoV-2 Lineage B.1.351; Beta (South_Africa/KRISP-K005325/2020) CF (UV Inactivated) (1 mL) |
| 0810614CFHI | SARS-CoV-2 Variant B.1.1.7 (Isolate:England/204820464/2020) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810614UV | SARS-CoV-2 Lineage B.1.1.7 Alpha Variant (England/204820464/2020) CF (UV Inactivated) (1 mL) |
| 0810616CFHI | SARS-CoV-2 Lineage P1; Gamma Variant (Japan/TY7-503/2021) CF (Heat Inactivated) (1 mL) |
| 0810616UV | SARS-CoV-2 Lineage P1; Gamma Variant (Isolate: Japan/TY7-503/2021) CF (UV Inactivated) (1 mL) |
| 0810617CFHI | SARS-CoV-2 Lineage P1_2021; Gamma Variant (NY-Wadsworth-21033899-01/2021) – CFHI (1.0 ml) |
| 0810618CFHI | SARS-CoV-2 Lineage P2_2021; Zeta Variant (NY-Wadsworth-21006055-01/2021) – CFHI (1.0 ml) |
| 0810619CFHI | SARS-CoV-2 Lso1 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810620CFHI | SARS-CoV-2 Lso2 Lin B.1.526_2021 Lota (NYWadsworth-21025952-01/2021) – CFHI (1.0 ml) |
| 0810621CFHI | SARS-CoV-2 Lineage B.1_2020 (NY-Wadsworth-103677-01/2020) – CFHI (1.0 ml) |
| 0810622CFHI | SARS-CoV-2 Lineage E3.1.595J2020 (NYWadsworth-33126-01/2020) – CFHI (1.0 ml) |
| 0810623UV | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (UV Inactivated) |
| 0810623CFHI | SARS-CoV-2 Lineage B.1.617.1 Kappa Variant (USA/CA-Stanford-15_S02/2021) CF (Heat Inactivated) |
| 0810624UV | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (UV Inactivated) |
| 0810624CFHI | SARS-CoV-2 Lineage B.1.617.2; Delta Variant (USA/PHC658/2021) CF (Heat Inactivated) |
| 0820010CFHI | VeroE6 Culture Fluid (Heat Inactivated) (1 mL) |
| 0801043 | Goat Anti-SARS-CoV-2 Polyclonal Serum (0.5 ml) |
| 0831042 | SARS-CoV-2 (recombinant) Stock (1 x 1.0 mL) |
| 0831043 | SARS-CoV-2 (E/ORF1ab recombinant) Stock (1 x1.0mL) |
| NATSARS-ST | Coronavirus SARS Stock (Qualitative) (1 mL) |
| NATCOV(229E)-ST | Coronavirus 229E Stock (Qualitative) (1 mL) |
| 0810229CFHI | Coronavirus (Strain: 229E) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810229 | Coronavirus Strain: 229E Lysate |
| 0810229UV | Coronavirus (Strain: 229E) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(NL63)-ST | Coronavirus NL63 Stock (Qualitative) (1 mL) |
| 0810228CFHI | Coronavirus (Strain: NL63) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810228 | Coronavirus Strain: NL63 Lysate |
| 0810228UV | Coronavirus (Strain: NL63) Culture Fluid (UV Inactivated) (1 mL) |
| NATCOV(OC43)-ST | Coronavirus OC43 Stock (Qualitative) (1 mL) |
| 0810024CFHI | Coronavirus (Strain: OC43) Culture Fluid (Heat Inactivated) (1 mL) |
| 0810024 | Coronavirus Strain: OC43 Lysate |
| NATMERS-ST | MERS-CoV Stock (Qualitative) (1 mL) |
| NATMR-BIO | NATtrol MERS Recombinant Pack (2x 0.2 ml +0.5 ml) |
| NATCOV(MR)-BIO | NATtrol MERS-S. Cerevisiae (0.6 ml) |
| 0810575 | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(1mg) |
| 0810575-0.5mg | MERS-COV (Strain: Florida/USA-2_Saudi Arabia_2014) Lysate(0.5mg) |
| CV033122 | COVID-19 Cross Over Panel (40x 1.0 ml) |
地址:武汉市洪山区光谷大道35号光谷总部国际时代 二期1栋1301
电话:15172469628
传真:18771149750
邮箱:sales@amyjet.com
0.2495